Adobe Garamond PRO (28pt).
• Part I: ex vivo LPS challenges were performed
• Part II: 3 subgroups of HV received an in vivo LPS
challenge immediately, 22 or 40 days after NI-0101 infusion
CD14
MD2
Ligand TLR4
MD2
TLR4
MD2
CD14
MyD88 X TRIFF
cF
b o
nly
cF
b-I
C
cF
b-I
C +
NI-
0101
cF
b-I
C +
Iso
typ
e
cF
b-I
C +
NI-
0101 D
265A
cF
b-I
C +
Iso
typ
e D
265A
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
TN
F
(p
g/m
L)
* * * * *
Cells a
lon
e
RA
SF
RA
SF
+ N
I-0101
RA
SF
+ Iso
typ
e
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
IL6
(p
g/m
L)
* * * * * * * *
NR R
0
2 0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
AC
PA
(IU
/mL
)
NR R
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
cF
b-I
C
(OD
45
0 n
m)
NR R
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
S1
00
A8
/A9
(
g/m
L)
NR R
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
HM
GB
1 (
ng
/mL
)
* * * *
NR R
-5
0
5
1 0
1 5
2 0
2 5
3 0
no
rma
liz
ed
de
lta
OD
NR R
-2
0
2
4
6
8
1 0
1 2
1 4
1 6
no
rma
liz
ed
de
lta
OD
NR R
-5
0
5
1 0
1 5
no
rma
liz
ed
de
lta
OD
NR R
-5
0
5
1 0
1 5
2 0
1 0 0
2 0 0
no
rma
liz
ed
de
lta
OD
* * * * *
b
0.00
0.01
0.10
1.00
10.00
100.00
1000.00
0 20 40 60 80 100 120
Th
ou
sa
nd
s (
ng
/mL
)
*: Anti-citrullinated protein antibodies
Top Related